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Abstract: Achieving high coverage of antiretroviral treatment (ART) in resource-poor settings will become increasingly 
difficult unless HIV incidence can be reduced substantially. Universal voluntary counselling and testing followed by 
immediate initiation of ART for all those diagnosed HIV-positive (universal testing and treatment, UTT) has the potential 
to reduce HIV incidence dramatically but would be very challenging and costly to deliver in the short term. Early 
modelling work in this field has been criticised for making unduly optimistic assumptions about the uptake and coverage 
of interventions. In future work, it is important that model parameters are realistic and based where possible on empirical 
data. Rigorous research evidence is needed before the UTT approach could be considered for wide-scale implementation. 
This paper reviews the main areas that need to be explored. We consider in turn research questions related to the provision 
of services for universal testing, services for immediate treatment of HIV-positives and the population-level impact of 
UTT, and the research methods that could be used to address these questions. Ideally, initial feasibility studies should be 
carried out to investigate the acceptability, feasibility and uptake of UTT services. If these studies produce promising 
results, there would be a strong case for a cluster-randomised trial to measure the impact of a UTT intervention on HIV 
incidence, and we consider the main design features of such a trial. 
Keywords: HAART, highly active antiretroviral therapy, HIV prevention, randomized controlled trials. 
INTRODUCTION 
 Despite impressive advances in the provision of 
antiretroviral therapy (ART) for HIV-infected individuals in 
resource-poor settings based on current treatment guidelines, 
only around one-third of the 15 million individuals who are 
eligible for treatment are currently receiving it [1]. 
Furthermore, for each patient started on ART, an additional 
two individuals become newly infected with HIV [1]. Unless 
the incidence of new HIV infections can be reduced, there 
will be a continuous increase in the number of HIV-positive 
individuals who will require ART in future. Achieving high 
coverage of ART will therefore become increasingly 
challenging in the absence of substantial reductions in HIV 
incidence. 
 Unfortunately, there are very few proven tools for HIV 
prevention. A review of randomised controlled trials (RCTs) 
of HIV prevention methods found that of 39 interventions 
tested in rigorously conducted RCTs, only 5 showed 
significant evidence of protection [2]. These included the 
three trials of male circumcision [3-5], the Mwanza trial of 
sexually transmitted infection (STI) treatment for HIV 
prevention [6] and the RV144 trial of a prime-boost vaccine 
regimen in Thailand [7]. Male circumcision reduces female-
to-male HIV transmission by 50-60%, but wide-scale 
implementation of safe services for male circumcision has 
been slow. The vaccine trial was of borderline significance 
and showed a modest effect, while STI treatment as an HIV 
prevention measure seems to be relatively less effective in 
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the mature epidemics which now predominate in sub-
Saharan Africa [8]. 
 The results of the Centre for the AIDS Programme of 
Research in South Africa (CAPRISA) 004 trial of tenofovir 
gel, showing a 39% impact on HIV incidence, have given 
renewed hope to the microbicide field [9]. The Preexposure 
Prophylaxis Initiative (iPrEx) trial of pre-exposure 
prophylaxis (PrEP) for men having sex with men (MSM) 
gave further hope for using antiretrovirals for prevention, 
with a 41% reduction in HIV incidence in those receiving an 
oral combination of daily tenofovir/emtricitabine [10]. 
Unfortunately a similar placebo controlled trial of PrEP in 
African women (FEM-PrEP) was discontinued early when it 
was deemed unlikely that the intervention could show a 
protective effect in the study population [11]. Further trials 
of ART-based microbicides as well as oral regimens for use 
as PrEP are in progress and will report in the next five 
years
*
. 
 Given the limited array of proven prevention tools, 
universal testing and treatment (UTT) has been proposed as 
a potential new HIV prevention strategy that may be highly 
effective in high prevalence settings [12-17]. UTT would 
                                                
*While this paper was in press, two RCTs (Partners PrEP and TDF-2) have 
found that the use of oral daily PrEP confers a significant reduction in HIV 
acquisition in heterosexual populations1,2. 
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involve offering HIV voluntary counselling and testing 
(VCT) to the entire population, and offering immediate ART 
to all those testing HIV-positive irrespective of clinical stage 
or CD4 count. Mathematical modelling has shown that UTT 
could lead to steep reductions in HIV incidence and might 
potentially eliminate HIV as a public health problem over a 
period of 15-20 years, as well as reducing HIV-related 
morbidity and mortality [12-16,18-20]. These projections are 
based on assumptions that have been questioned, however, 
and some have argued that the likely effects of a UTT 
intervention would be much more limited [21,22]. 
Furthermore, implementation of UTT on a wide scale would 
be logistically and financially challenging, and might 
overwhelm existing health services. 
 A trial that was recently halted early, due to unequivocal 
evidence of a protective effect of early ART, currently 
provides the most persuasive data to support universal 
treatment to prevent transmission. The HIV Prevention 
Trials Network (HPTN) 052 study included 1700 discordant 
couples (97% heterosexual) in which one partner was 
infected with HIV and had a CD4 count between 350 and 
550 cells/mm
3
, from 13 sites in Africa, Asia, and the 
Americas [23]. Only one case of HIV transmission occurred 
among the couples assigned to receive immediate treatment 
(median CD4 count at entry was 436 cells/mm
3
) compared to 
27 cases among those in the delayed treatment arm 
(treatment onset at CD4 count <250 cells/mm
3
), representing 
a 96% reduction in HIV transmission to the uninfected 
partner. 
 Before UTT is considered for implementation on a wide 
scale, it is important that rigorous evidence is collected on 
the feasibility and effectiveness of the UTT strategy, and on 
any adverse effects of the intervention including toxicity or 
the development of ART resistance. In this paper, we discuss 
the main research questions that need to be addressed in 
collecting this evidence and the research methods that could 
be used to answer them. We begin by discussing research 
issues related to the provision of universal VCT before going 
on to explore issues in the provision of immediate treatment 
and care for all those diagnosed HIV-positive. We then 
consider research to determine the effects on HIV 
transmission at individual and population levels. We 
conclude that a large-scale cluster-randomised trial would be 
needed to measure the impact of UTT on HIV incidence at 
population level, and briefly discuss some of the design 
issues in implementing such a trial. We focus here on 
research on UTT in sub-Saharan Africa, where there is the 
most urgent need for effective HIV control. 
UNIVERSAL HIV COUNSELLING AND TESTING 
Introduction 
 Awareness of HIV status is the first step in accessing 
care, and has been strongly advocated not only as a potential 
prevention tool but also as a way to normalise and de-
stigmatise HIV [24]. However, it is estimated that less than a 
quarter of 15-49 year olds in sub-Saharan Africa know their 
HIV status [1]. In order to make UTT achievable, a better 
understanding of the barriers to testing, knowledge of test 
result and subsequent linkage with care must be gained to 
make important operational changes to service provision. 
 In recent years, progress in extending coverage and 
uptake has been made through provision of vertical and 
integrated services, client- and provider-initiated HIV 
counselling and testing, opt-in and opt-out approaches and 
other innovative methods such as home-based and work-
place testing [25-30]. These achievements have to be built 
upon for UTT, but operational research is required to 
examine the acceptability, effectiveness, feasibility and 
sustainability of these approaches. Mixed methods research, 
combining qualitative and quantitative approaches, will be 
needed to provide insights to patient behaviour [31]. 
Findings from studies done in the current context of 
relatively low access to testing and treatment, and with ART 
reserved for those with advanced immune suppression, may 
not be generalisable to a future UTT model where 
individuals without significant HIV-related illness are 
invited to initiate ART. Therefore, questions already 
examined in existing contexts may need to be re-examined in 
the context of UTT. 
 In this section, we discuss research questions relating to 
models of service provision, promotion of universal testing, 
methods and frequency of testing, counselling strategies, 
uptake, community-level response and costs. Key research 
questions and potential research methods are summarised in 
Table 1. 
Models of Service Provision 
 The most suitable model of service provision may vary 
depending on the context and setting where UTT is to be 
implemented. Nonetheless, when developing a model of 
care, there are key questions that would be relevant for any 
setting. Various models of VCT provision have been used to 
date, and it appears that ease of access to testing and 
receiving a result is the most critical determinant of uptake. 
Work-place and home-based testing have been shown to be 
advantageous [25,30,32], as has community-based VCT 
provision when compared to standard clinic-based provision 
[33]. However, questions remain concerning how well these 
modes of testing will lead to linkage with treatment and care; 
what are the implications with respect to confidentiality, 
stigma or pressure to accept a test; and the sustainability of 
such work-place and home-based services in the long term 
given numerous competing priorities and pressures on 
resources. 
 A variety of models will need to be examined, including 
door-to-door campaigns and home-based testing; work-place 
VCT services; mobile test units that visit communities 
periodically; stand-alone VCT centres in conveniently placed 
communal locations (e.g. market-places, bus-stands, 
religious venues); or on-site VCT within health units, 
provided either as a stand-alone service or integrated within 
healthcare provision in an “opt-out” model. It is important to 
examine multiple options as there will be population sub-
groups to whom some models will not be available or 
acceptable, and alternatives should exist if high uptake is to 
be achieved. Additionally, VCT provision models should 
consider extending services provided through UTT to ensure 
access to proven prevention tools such as male circumcision, 
condoms or microbicides (if licensed in the future). 
Standardised client identification and record keeping will be 
necessary to co-ordinate testing efforts and ensure more 
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accurate analysis of attendance across testing and care sites, 
as duplication may be a problem. Qualitative research with 
users and non-users of different types of services, as well as 
service providers, will provide useful insights. 
Staff Requirements for HIV VCT 
 Given the severe human resource shortages in many sub-
Saharan African countries, task-shifting has become the 
mainstay of HIV care and perhaps most widely in provision 
of VCT. Yet the evidence regarding task-shifting in VCT is 
relatively limited [34]. The minimal cadre of health care 
worker required to deliver an adequate level of service and 
the number of trained staff and other resources required to 
carry out universal testing need further exploration. 
Community health workers, lay counsellors and even “expert 
patients” may provide the most feasible option for roll-out of 
UTT. When assessing these questions, the quantity and 
quality of service provided by a given model of testing needs 
to be examined. Operational research is needed to examine 
the volume of clients that a given cadre of staff is able to see, 
the accuracy of results given (by comparing VCT results 
against gold standard laboratory testing) and client 
satisfaction with the quality of service provided. 
 Self-testing using oral swabs [35,36] and oral fluid test 
kits has been explored as a model to increase knowledge of 
HIV status. Encouraging results were found in a preliminary 
study in Malawi, where 95% of adults selected for study 
were seen, and 92% of these opted for self-testing [37]. The 
validity of their test results was shown to be close to 100%. 
While this approach may be controversial, it may provide an 
additional method which is discreet, easy and non-invasive 
to perform and appealing to those who are reluctant to use 
other services and may encourage repeat testing. Care will be 
needed to ensure that patients who test HIV-positive are 
linked to services for provision of counselling and treatment. 
 Integrating HIV testing into the care of patients 
presenting with conditions such as tuberculosis (TB) and in 
antenatal care facilities has been successful [38,39], but the 
offer of an HIV test to any individual engaging with a health 
Table 1. Key Research Questions Related to Counselling and Testing in Universal Testing and Treatment (UTT) and Suggested 
Research Methods 
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Models of service 
provision 
• Where should VCT services be provided? 
• Who should deliver VCT? 
• What is the added role of self-testing? 
• What is the role of expanded PIT in medical settings? 
? ? (?) 
  
Promotion of universal 
testing 
• What beliefs and perceptions need to be understood to appropriately 
target promotion of UTT in a given community?  
 ? ?   
 • Which subsets of the population are captured by different modes of 
promotion? 
• What modes of promotion are most effective in achieving uptake of 
testing? 
? ? ? 
  
Test methods • What is the predictive value of POCT in the context of UTT for a 
given population prevalence of HIV? 
 ?    
Frequency of testing • What frequency of testing (and treatment) is needed to reduce the 
R0 of HIV to <1? 
   ?  
Counselling strategies • What is the evidence on the effectiveness of pre-test counselling 
approaches?  
? ? ?   
 • How does post-test counselling affect behaviour change, HIV 
incidence and repeat testing? 
? ?    
 • How does group pre-test with individual post-test counselling 
compare with individual pre and post-test counselling? 
? ? ?   
Uptake of testing • What are the barriers to testing? 
• What aspects of service provision ameliorate identified barriers? 
  ?   
 • What proportion of a given community has participated in VCT and 
repeat testing? 
• What factors are associated with non-uptake and failure to re-test? 
 ?  
  
Costs • What are the training, staffing, equipment and site costs?   ?  ? ? 
UTT, Universal Testing and Treatment; VCT, Voluntary Counselling and Testing; PIT, Provider-Initiated Testing; POCT, Point-of-care Testing. 
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care facility in an expanded provider-initiated testing model 
(opt-out testing for all clinic and hospital patients) has yet to 
be assessed [40,41]. This could be an important opportunity 
to capture missed diagnoses especially as HIV may be the 
underlying cause of a given presentation for medical care. 
Promotion of Universal Testing 
 Before embarking on a UTT programme, understanding 
should be gained of likely community perceptions of UTT 
and how best to promote UTT in a wide-reaching, simple 
and clear way [42]. 
 Imperative in exploring community perceptions are 
questions relating to what concerns exist over UTT. Would 
there be fear of forced testing or abuse of test results? Would 
there be mistrust of UTT and its purpose as a public health 
prevention tool, given that treatment has previously been 
reserved for individual benefit? These are difficult but 
important issues where context-specific understanding is 
needed in order to allay fears and communicate effectively to 
pre-empt a negative reaction. Focus group discussions with 
community leaders and selected representative groups within 
the population could be combined with key informant 
interviews or standardised questionnaires. 
 It is possible that low rates of testing are due partly to the 
perception that being diagnosed HIV-positive has only 
adverse effects, with no immediate benefit if treatment is not 
offered. The UTT strategy, incorporating the offer of 
immediate treatment, may overcome this disincentive to test 
and lead to higher uptake of VCT. This hypothesis needs to 
be evaluated. 
 Answers to the above questions would help inform the 
content of different modes of promotion of universal testing. 
Publicity using radio and newspapers and printed materials 
such as posters and leaflets are common methods used in 
health promotion [43,44]. When developing such publicity 
materials, data should be collected on understanding of and 
responses to different materials. During subsequent testing 
campaigns, data collected from those presenting for testing 
on their exposure and response to different promotion 
methods might guide the design of future campaigns. 
Patterns may emerge when data are matched with individual 
demographics (e.g. by age and sex) to analyse whether 
different promotion methods are effective in different 
population sub-groups. 
 A large scale multi-disease prevention package has been 
studied and shown to be highly effective in drawing large 
numbers of individuals at a community level to test by 
simultaneously offering VCT for HIV alongside provision of 
condoms, insecticide-treated bed nets and water filters [45] 
and optimises use of resources and opportunities. This 
integrated approach has the advantage of addressing multiple 
health promotion needs of a community and warrants further 
investigation in other settings. 
HIV Testing Methods 
 Most VCT services use rapid point-of-care tests (POCTs) 
for HIV infection, so that results can be provided rapidly to 
clients during the same visit [46]. The sensitivity, specificity  
 
and predictive values of these POCTs may need to be re-
examined to determine whether these assays are reliable in 
the context of UTT. Limitations of POCTs have been 
identified [47-49] and, in the context of universal treatment, 
the concern is that ART may be initiated without 
confirmatory testing or assessment of CD4 count or other 
clinical parameters. The implications of false-positive results 
are therefore more serious than at present where 
immunological or clinical markers confirm immune 
suppression. Low specificity and positive predictive value of 
a POCT could lead to unnecessary treatment of HIV-
negative individuals. Algorithms involving use of multiple 
POCTs, with laboratory confirmation for the small number 
of discordant or indeterminate results, may provide adequate 
performance but challenge resources. 
 Individuals with acute stage HIV infection, tested before 
they develop detectable antibody levels, will not be detected 
using current HIV POCTs. Although the point prevalence of 
such infections at the population level may be low, such 
individuals may contribute disproportionately to onward 
HIV transmission for both biological and behavioural 
reasons [50-57]. Hence, failure to detect and treat such 
individuals may significantly undermine the impact of UTT. 
The current methods to address this issue are limited. One 
option is to increase the frequency of HIV VCT (e.g. up to 
monthly), although this may not be practically feasible and 
may still miss a proportion of acute infections. This could be 
minimised by using laboratory-based fourth-generation HIV 
assays, but even with this technology a small number of 
highly infectious ‘acute cases’ will still be missed. 
Moreover, the use of these assays in African settings is 
called into question due to high rates of false positivity 
related to co-infection with other endemic organisms [58]. 
Currently under investigation is a combination antigen-
antibody POCT [59] which has yet to be validated, but may 
miss fewer acute infections. Alternatively, HIV nucleic acid 
amplification testing (NAAT) of HIV antibody-negative 
patients presenting with symptoms consistent with acute 
HIV infection has been proposed [60]. 
Frequency of Testing 
 Information is needed on the frequency of testing that 
should be recommended for a UTT programme. The only 
evidence concerning this specific issue is from mathematical 
models. Some mathematical models predict that annual HIV 
VCT is sufficient to confer a substantial reduction in HIV 
incidence in a high prevalence setting in sub-Saharan Africa 
[12,13,15-17]. Other models have shown that in populations 
with little variation in risk behaviour and random mixing, a 
95% reduction in incidence could still be achieved if 80% of 
the population accepted HIV testing once every 3-4 years 
[14]. Further modelling, informed by empirical data on 
uptake of testing and re-testing, is needed to elucidate the 
choice of frequency of testing under a range of conditions. 
 Operationally the continued provision of frequent HIV 
VCT will be challenging and costly, and could potentially 
lead to population-level testing fatigue. The normalisation of 
HIV testing, opt-out testing and potential self-testing may be 
important strategies to investigate in the context of trials to 
deliver and evaluate frequent testing. 
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Counselling Strategies 
 Existing models of counselling prior to an HIV test are 
generally not evidence-based [61] and there have been doubts as 
to whether pre-test counselling confers any benefit [62]. Current 
United States Centers for Disease Control and Prevention 
(CDC) guidelines only require informed consent for an HIV 
test, as for any other medical test, and pre-test counselling is not 
mandatory [63]. It is unclear whether VCT leads to the adoption 
of safer sexual behaviour, with conflicting findings from 
different studies [64,65]. A trial comparing two VCT delivery 
strategies in Zimbabwe found that HIV incidence was higher in 
the high-uptake VCT arm [30,66]. 
 In the context of UTT, we need to examine whether 
counselling has an added role in changing attitudes to 
treatment - from the current understanding that treatment is 
for the very sick, to the concept of treatment irrespective of 
CD4 count or World Health Organization (WHO) stage. 
Different models of counselling could be compared in 
observational studies, and linkage with testing and 
subsequent uptake of treatment measured. Qualitative 
assessment of the added value of any such counselling would 
be informative both from user and provider perspectives. 
 As task-shifting options are considered, the acceptability 
- especially with respect to confidentiality - of using lay or 
community members to provide counselling must be 
examined and qualitative studies among non-users of 
services will be of particular importance. 
 Group pre-test counselling is used as a method to scale 
up VCT in many countries where low staffing levels struggle 
with the burden of clients attending for counselling and 
testing [67]. The capacity of group counselling to address 
pre-test issues in the context of UTT should be explored. 
Finally, where burden of workload is high, the impact on 
providers and how they cope warrant investigation. 
Uptake of Testing 
 Against the current backdrop of inadequate coverage and 
uptake, universal HIV testing is an ambitious goal. Routinely 
collected data from testing venues would provide the starting 
point to compare the reach of different models in terms of 
numbers testing and receiving their test results. More 
difficult will be ascertaining the proportion of a given 
population who have been tested. Accurate population 
information must be obtained and account will need to be 
taken of overlapping or ill-defined catchment areas of testing 
facilities, repeat testing at different facilities, and population 
migration and mobility. 
 Studying demographic associations with uptake of testing 
provided under different models of service provision would 
provide useful insights into which sub-groups of the 
population require further exploration and targeting, relating 
to gender, ethnicity, religion, socio-economic or educational 
characteristics. 
 Community-wide feasibility studies of pilot UTT 
programmes would provide a valuable opportunity to collect 
detailed data on uptake of testing, and to investigate reasons 
for uptake or non-uptake of testing using a combination of 
quantitative and qualitative methods. Such feasibility studies 
could also examine uptake of repeat testing and uptake of 
testing at different test sites, and could incorporate 
quantitative and qualitative studies of community and health-
worker perceptions of the VCT programme. 
Costs 
 Cost-effectiveness studies of the various methods that 
may be piloted hold the key to identifying which strategies 
will be feasible for ministries of health and other providers 
who have to find sustainable ways to provide services with 
limited resources. 
UNIVERSAL HIV TREATMENT 
Introduction 
 Most countries in sub-Saharan Africa are struggling to 
maintain treatment initiation even for those meeting the 
current guidelines [68]. In the current environment, 
expanding access to ART for asymptomatic patients with 
higher CD4 counts, and offering immediate treatment to all 
HIV-positive individuals as required by the UTT strategy, 
will clearly be very challenging. 
 This section discusses some of the key issues and 
research questions that need to be addressed relating to 
linkages between testing and treatment, models of treatment 
provision, choice of treatment regimen, approaches to 
follow-up and monitoring, uptake and adherence, effects on 
other health services and costs. All such research will require 
effective community engagement and close collaboration 
with the existing health services. Key research questions and 
potential research methods are summarised in Table 2. 
Linkages Between HIV Testing and Treatment 
 Current strategies to link those accepting VCT and found 
to be HIV-infected to services providing further clinical 
assessment and, if appropriate, initiation of ART often do 
not work effectively. Although this review focuses on 
research questions relating to UTT in Africa, data from other 
settings may be informative. An ongoing study in 
Washington, District of Columbia (DC) reported only 50% 
acceptance of referral to ART provision centres among those 
testing HIV-positive [69]. A national testing programme in 
South Africa reported successful testing of 1.7 million 
individuals between April and July 2010 but, of 300,000 
HIV-positive subjects, only half were referred to any related 
health services and only an additional 3000 initiated ART 
during the first two months of the programme [70]. Barriers 
to accessing care include limited accessibility and co-
ordination of services and lack of community engagement in 
programme planning [71]. Clearly, for a UTT programme to 
succeed in providing immediate ART for a large proportion 
of diagnosed HIV-positive patients in the community, 
challenges to linkage of services need to be addressed. 
 Physical proximity of testing and treatment sites, and 
convenient opening hours may address some of the barriers 
to linkage. In addition, assigning community health workers 
to individual patients to facilitate access to treatment, and 
trace those who test HIV-positive but do not present for 
treatment, could also facilitate linkage. An observational 
study has described the successful use of self-selected 
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community ART groups to facilitate ART delivery and 
adherence
72
 and the extension of this concept to testing and 
linkage to care should be explored. However, the potential 
problems of lack of confidentiality and coercion, and 
consideration of non-participants, require close scrutiny in 
qualitative studies. In the absence of data supporting any one 
model of linkage to care, operational research is needed to 
evaluate such approaches. 
Models of Treatment Provision 
 Different approaches to treatment provision may be 
needed in different settings, and operational research and 
pilot studies will be needed to assess their feasibility and 
effectiveness. Some possible models are reviewed below but, 
to maximise coverage, a combination of approaches may be 
necessary. 
 Home-based care: Whether or not VCT is provided 
through a door-to-door campaign, it may be possible to offer 
treatment and follow-up through a continuous system of 
home-based care. Such approaches have been shown to be 
effective and cost-effective in previous research in Uganda 
[73], although they usually incorporate some clinic visits. 
Advantages of this approach are that it shields newly 
diagnosed individuals from community scrutiny, does not 
require the construction of new facilities and may be more 
acceptable at a community level. Disadvantages include a 
high work-load for staff, disclosure within the home which 
may be associated with gender-based violence [74], and 
difficulties in accessing patients who are usually at work 
during the day unless evening visits are feasible. 
 Facility-based provision: This is the standard approach at 
present but could be adapted to offer extended access to 
ART by increasing staff, clinic space or opening hours. An 
important issue is whether it is feasible to provide and 
monitor ART effectively at lower level health units than 
have traditionally provided ART, and this is related to the 
question of which cadres of staff are able to provide 
treatment. Integration of ART with other health services, for 
example those providing treatment for TB, maternal and 
child health care or family planning services, could also be 
considered for further exploration [75-77]. 
 Community treatment centres: If existing health facilities 
are not close enough to local communities, consideration 
could be given to establishing community-based treatment 
centres. These could either be permanent facilities or mobile 
clinics linked to locations such as markets, schools or 
religious venues, or could involve drug delivery at 
community level for stable patients, as an extension of 
facility-based provision [72]. 
 Work-place provision: This would probably be most 
appropriate at sites where there is a large workforce 
employed in a particular occupation, such as mines or 
plantations. Work-place VCT has been well accepted [30] 
and expansion of these facilities to ART provision would be 
a potentially effective method of delivering treatment. 
 Irrespective of the venue at which ART is provided, one 
of the key barriers to effective service provision is the 
shortage of trained health-care professionals to deliver 
therapy. While treatment of advanced stage HIV disease is 
often complicated by immune reconstitution inflammatory 
syndrome (IRIS), profound immunosuppression and 
opportunistic disease [78], provision of ART for 
asymptomatic individuals is likely to be less complex and 
might be delegated to less highly-qualified staff such as 
nurses or clinical officers. In a UTT programme, there will 
be a broad spectrum of HIV-positive patients requiring 
treatment, including both early and late stage infections. 
Task-shifting may be the only feasible approach given the 
large number of HIV-positive patients requiring treatment. 
Triage systems may be needed to ensure that those 
presenting with late-stage disease or with HIV-related 
illnesses are identified and treated by appropriately qualified 
staff and in suitable sites, while those who are well can be 
managed through mechanisms more adapted to lifestyle 
needs of healthy patients. 
Choice of Treatment Regimens 
 The choice of a safe, effective and acceptable first-line 
ART regimen that can be used irrespective of CD4 count in a 
UTT programme is critical in order to limit the potential 
development of drug resistance, drug-related toxicities and 
poor adherence. The regimen should be chosen to minimise 
pill burden and avoid need for refrigeration in order to 
increase adherence. The first-line regimen currently 
recommended by WHO [68] comprises tenofovir, 
emtricitabine and efavirenz or nevirapine. This would 
potentially be an appropriate choice for use in UTT, but 
clinical studies are needed to confirm this. Nevirapine-based 
regimens, whilst safe and well-tolerated for advanced stage 
disease with good safety data in pregnancy, confer risk of 
hepatic toxicity especially in women and in those with high 
CD4 counts (>350 cells/mm
3
). Although tenofovir/emtricitabine 
(or lamuvidine) and efavirenz may be the easiest, safest and 
most readily available option as recommended first-line 
therapy, the genital tract penetration of efavirenz is sub-
optimal and could potentially lead to population-level 
development of transmitted drug-resistant variants. This 
latter aspect would require evaluation in UTT. Second-line 
therapy must also be available for those individuals unable to 
take first-line treatment due to toxicity, concomitant illness 
or drug resistance and treatment failure, and should adhere to 
national and WHO treatment guidelines. 
 Although there is emerging evidence of enhanced 
survival benefits with earlier ART [79,80], the optimal time 
to initiate ART for individual patient benefit remains 
uncertain [81-83]. While outcome is improved if ART is 
started in the presence of opportunistic infections and 
especially TB [84], how early to start ART in asymptomatic 
individuals is unknown [85]. This is currently under 
investigation in the Strategic Timing of Antiretroviral 
Treatment (START) trial, a randomised controlled trial 
(RCT) examining the effects of early initiation of ART (CD4 
>500 cells/mm
3
) compared with current treatment guidelines 
(CD4 <350 cells/mm
3
) which will report in 2015 [86]. The 
use of ART outside current national and WHO treatment 
guidelines will require careful discussion with local 
stakeholders and national authorities. 
 Any ART agent may be associated with drug-related 
toxicities [87], for example tenofovir with renal impairment 
[88] and zidovudine with anaemia [89]. The 2NN study 
reported an association of nevirapine with an increased 
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frequency of serious adverse events among patients with 
high CD4 counts [90]. In addition, although there have been 
concerns over the potential teratogenic effects associated 
with efavirenz [91,92], a more recent meta-analysis has 
found no increased risk of birth defects among women 
exposed to efavirenz during the first trimester of pregnancy 
compared with other ART agents [93]. A reasonable strategy 
to test the UTT approach would be to adopt one of the 
currently recommended first-line therapy regimens, avoiding 
the use of stavudine wherever possible. Clearly, this may 
pose feasibility concerns in resource-limited settings which 
are struggling to progress to the recently recommended first-
line regimen, despite the availability of generic once daily 
formulations and recent price reductions [94]. Clinical 
research is needed to evaluate the acceptability, tolerability 
and cost-effectiveness of alternative first- and second-line 
regimens when delivered in a UTT programme to 
asymptomatic patients with high CD4 counts as well as 
patients with more advanced immunosuppression. Data can 
be obtained from observational studies and potentially from 
RCTs. 
Approaches to Monitoring and Follow-Up 
 Routine inclusion of laboratory-based testing involves 
additional logistical, resource and staff constraints, 
potentially undermining the feasibility of delivering an 
effective UTT programme. Depending on the disease stage 
of the individual patient and choice of ART regimen, toxicity 
monitoring should be kept to the minimum required to avoid 
increased risk to the patient. The Development of 
Antiretroviral Therapy in Africa (DART) trial established the 
safety and long-term sustainability of ART provision without 
laboratory-based monitoring in rural Uganda and Zimbabwe, 
although after 2 years there was a slight difference in 
mortality between the two arms of the trial [81,95]. Many 
patients on immediate treatment in a UTT model will be at 
an earlier stage of HIV disease progression than those in the 
DART trial, but there is no reason to believe that they will 
have greater monitoring needs, and the DART findings 
remain relevant for UTT. 
 The level of monitoring required will vary according to 
treatment regimen, but if standard first-line therapy is 
employed this could be minimal. Renal toxicities could be 
monitored using urine protein/albumin levels tested by 
dipstick as an initial screening procedure. Only those with 
significant proteinuria would then be referred for blood 
testing. Management of any complications would be 
according to national guidelines and would necessitate full 
laboratory tests as indicated. It will not be feasible when 
developing the UTT concept to regularly monitor CD4 
counts or viral load using current laboratory-based testing. 
The introduction of POCTs for CD4 count [96] may make 
this more feasible, although these tests will require careful 
field evaluation. 
 The adequacy of monitoring and follow-up will need 
careful assessment in feasibility studies and RCTs of UTT 
interventions. For example, a random sample of patients in 
such studies could be monitored more frequently or using 
additional laboratory tests (e.g. renal and liver function, 
blood cell counts) and the data used to assess the potential 
adequacy of less intensive follow-up schedules. 
Adherence to ART 
 The risk of developing viral resistance to ART is directly 
linked to adherence to therapy [97] and drug choice, with 
enhanced viral suppression conferred by boosted protease 
inhibitor- or non-nucleoside reverse transcriptase inhibitor-
containing regimens compared with triple nucleoside reverse 
transcriptase inhibitor combinations [98]. Stopping ART due 
to concomitant ill health, drug supply problems, ambivalence 
to continuing therapy or cultural and health beliefs confers 
not only increased risks of adverse events [99-101] but 
additional problems associated with viral rebound leading to 
enhanced risk of onward transmission or the development of 
drug resistance [102,103]. 
 Adherence may be reduced in a UTT programme, since 
many of the patients started on ART may have had no 
clinical symptoms associated with their HIV infection. 
Patient messaging will need to be adapted taking this new 
treatment paradigm into account. Levels of adherence will 
need careful assessment in feasibility studies and RCTs of 
UTT interventions. Data from such studies can be used in 
mathematical modelling to predict the likely long-term 
effects of sub-optimal adherence on drug resistance and HIV 
transmission. 
Uptake of Treatment 
 Uptake of immediate ART can be expected to vary in 
different settings [69,104] and feasibility studies are needed 
to measure the actual uptake achieved by different UTT 
approaches in different areas in sub-Saharan Africa. Such 
studies will require careful definition of the denominator 
population of individuals who test positive through any of 
the testing services provided, paying careful attention to the 
need to avoid double counting if individuals test at more than 
one centre. A definition will also be needed for “immediate” 
uptake of treatment, which might for example be taken as 3 
months from the time of HIV diagnosis. 
 By selecting random samples of those accepting and 
declining immediate treatment, and using a mix of 
quantitative and qualitative methods, the same studies could 
investigate reasons for not taking up the offer of immediate 
ART. The findings of such studies could be used to further 
improve the services to overcome barriers to uptake of 
treatment. 
Outcome of Treatment 
 Feasibility studies of UTT programmes will also need to 
collect detailed data on the outcomes of treatment. These 
may include retention under follow-up, adherence to 
treatment, adverse effects, viral suppression and the 
development of drug resistance. Some of these outcomes 
could be measured through more intensive observations on a 
random sample of patients starting on treatment. Case-
control studies could be performed on patients with good and 
poor outcomes to investigate risk factors for poor outcomes. 
As for testing services, qualitative studies could provide 
valuable information on patient and health-worker 
perceptions of the treatment programme and how it could be 
improved. 
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Effects of UTT on Health Services 
 There are concerns that substantial increases in numbers 
of patients on ART could lead to over-burdening of poorly-
resourced and understaffed health facilities, leading to 
adverse effects on health services. Conversely, effective 
ART provision for a high proportion of HIV-positive 
individuals in a community should lead to substantial 
decreases in HIV-related morbidity, and this should reduce 
the incidence of opportunistic infections requiring diagnosis 
and treatment. A study in Zambia showed ancillary benefit to 
routine clinical services when disease-specific research was 
combined with service delivery [105]. Observational studies, 
for example during feasibility studies or RCTs, should be 
carried out to collect detailed data on clinic burden and on 
the delivery of other routine health services. 
 It has been suggested that the efficiency of service 
delivery could be increased if ART delivery could be 
integrated with the provision of treatment and care for other 
chronic conditions, including TB and non-communicable 
diseases such as diabetes and hypertension, which are 
increasing in incidence in many parts of sub-Saharan Africa. 
Operational research is needed to explore such treatment 
synergies. 
Costs 
 Policy decisions on implementation of the UTT strategy 
will depend critically on reliable cost-effectiveness 
estimates, particularly since initial costs of UTT roll-out may 
be very high. Detailed costing studies must be incorporated 
in feasibility studies and other operational research studies of 
UTT to provide the basis for such cost-effectiveness 
estimates. Drug costs comprise only a small part of the 
Table 2. Key Questions Related to Treatment in Universal Testing and Treatment (UTT) and Suggested Research Methods 
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Linkages between 
testing and treatment 
• How well does a given VCT model achieve linkage with treatment? 
• What factors act as barriers to uptake of treatment after testing positive? 
• What programmatic factors are associated with better linkage between testing 
and treatment initiation? 
? ? ? 
  
Models of treatment 
provision 
• Which models of treatment provision are most effective and acceptable? 
• Where should treatment be provided? 
• Who should deliver these treatment services? 
? ? ? 
  
Choice of treatment 
regimens 
• Which treatment regimens are safe, effective and acceptable to use as first-line 
treatment? 
? ? (?)   
 • Which treatment regimens are feasible and sustainable for use in resource-
limited settings? 
? ? ?   
 • Which treatment regimens are associated with ART failure and drug resistance at 
different time points? 
? ?    
Monitoring and 
follow-up  
• What are the monitoring requirements of a given treatment regimen? ? ?    
 • Are there different monitoring requirements for patients who were sick when 
they started treatment compared with those who were well? 
? ? ?   
 • What are the evolving challenges in maintaining follow-up over time?  ? ?   
Adherence to ART • What patient factors are associated with good adherence (>90%) at different time 
points on treatment? 
 ? ?   
 • What programmatic factors are associated with good adherence at different time 
points on treatment? 
 ? ?   
Uptake of treatment • What proportion of HIV-infected individuals in a population are on treatment at 
different time points? 
 ?    
 • What is the impact of a given proportion on treatment on HIV transmission?    ?  
Effects of UTT on 
health services 
• What is the impact of UTT on health services in a given location? 
 ? ? ? ? 
 • What are the cost implications (financial and human resources) of UTT over 
time, including costs averted? 
  ? ? ? 
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overall cost of delivering immediate ART, and account  
needs to be taken of other costs including personnel, 
laboratory testing, training, supervision, monitoring and the 
costs of referral and second-line treatment. 
EFFECTS OF UTT ON HIV TRANSMISSION 
Introduction 
 Previous sections have discussed operational research 
relating to the provision of services to deliver the UTT 
strategy. If the strategy is shown to be feasible and 
acceptable in resource-poor settings in sub-Saharan Africa, 
the next question is what impact this would have on HIV 
infection. In this section, we discuss the research that will be 
needed to determine the effect of UTT on HIV transmission 
both at individual and population levels. We also consider 
studies to examine the cost-effectiveness and adverse effects 
of the intervention. Key research questions and potential 
research methods are summarised in Table 3. 
Effects of ART on HIV Transmissibility at Individual 
Level 
 Model projections of the impact of UTT on HIV 
transmission depend on assumptions regarding the effect of 
ART on HIV transmissibility from an HIV-infected 
individual to his or her sexual partners. HIV plasma viral 
load is known to be a key determinant of HIV 
transmissibility [106,107] and ART, if delivered effectively, 
reduces plasma viral load to an undetectable level in a high 
proportion of patients [108]. It is therefore assumed that 
ART will reduce the risk of HIV transmission to a very low 
level. For accurate modelling, however, more precise data 
are needed on effects of ART on transmissibility. These data 
are also needed to give clear and accurate information to 
HIV-positive patients on ART concerning the risk of 
transmitting HIV to their sexual partners, and this is clearly 
of special concern in HIV-discordant long-term partnerships. 
 The early termination and results of the HPTN 052 trial 
have been described earlier [23]. As initiation of ART at 
Table 3. Key Questions Related to Population-Level Effects of Universal Testing and Treatment (UTT) and Suggested Research 
Methods 
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Effect of UTT on HIV 
transmissibility at 
individual level 
• What are the effects of ART on genital shedding of HIV? 
• What are the effects of ART and different levels of genital HIV shedding on risk of 
transmission to sexual partners? 
• What are the effects of ART on HIV transmissibility in the presence of concomitant 
sexually transmitted infections? 
? ?  (?)  
Effects of UTT on HIV 
transmission at 
population level 
• What proportions of new HIV infections are attributable to index cases at different 
CD4 counts and HIV clinical stages?  ?  ?  
 • What is the impact of UTT on population-level HIV incidence at different time 
points? 
• How does the impact of UTT on HIV incidence depend on key process variables 
such as uptake of testing and treatment, adherence and retention?  
? (?)  ?  
Other effects of UTT • What are the effects of UTT on HIV-related morbidity and mortality? 
• What are the effects of UTT on the incidence and prevalence of TB and other 
opportunistic infections? 
• What are the effects of UTT on vertical transmission of HIV? 
• What are the effects of UTT on the incidence of treatment failure, toxicity and drug 
resistance? 
• Is delivery of UTT associated with behavioural disinhibition? 
? (?) ? ?  
Cost-effectiveness of 
UTT for HIV 
prevention 
• What are the total per capita costs of implementing a UTT programme at population 
level? 
• What cost savings are provided by reductions in HIV incidence and HIV-related 
morbidity? 
• What is the overall cost-effectiveness of UTT expressed per HIV infection averted or 
per DALY? 
• How do the effectiveness and cost-effectiveness of UTT compare with those of more 
limited treatment programmes? 
? (?)  ? ? 
UTT, Universal Testing and Treatment; ART, Antiretroviral Therapy; TB, Tuberculosis; DALY, Disability-adjusted Life Year. 
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higher CD4 counts is considered, further research will be 
needed to measure the effects of immediate versus deferred 
treatment on both HIV transmission and HIV-related 
morbidity and disease progression. 
 Trials looking directly at transmission by following up 
HIV-discordant partners are logistically challenging, and 
need to be large since transmission rates are often reduced to 
low levels because the HIV status of the partnership is 
known and intensive prevention counselling is delivered for 
ethical reasons. Despite limitations related to selection 
effects and confounding, it is therefore likely that most data 
will continue to come from observational studies in which 
HIV incidence in HIV-discordant couples is examined in 
relation to the ART treatment status of the HIV-positive 
index case. In a recently published landmark study, an 
observational analysis was carried out among 3381 HIV-
discordant couples taking part in a multi-centre RCT of 
Herpes suppressive therapy for HIV prevention [109]. In 
these couples, the HIV-positive index partner initially had a 
CD4 count of 250 cells/mm
3 
or over and did not meet 
national guidelines for ART initiation. Subsequently, 349 
index cases commenced ART and the adjusted rate ratio for 
HIV infection in their sexual partners compared with those 
not on ART was 0.08, indicating a 92% reduction in the risk 
of HIV transmission, and only one genetically-linked HIV 
transmission was observed among those on ART. However, 
the confidence interval for the rate ratio was very wide (0.00 
- 0.57) and further data are needed to obtain more precise 
estimates. As well as further observational analyses based on 
current and future cohorts of patients on and off treatment, 
there will be a place for further systematic reviews bringing 
together all available data on this question. 
 Genital shedding of HIV is known to be increased in the 
presence of other sexually transmitted infections (STIs), 
which are highly prevalent in some parts of sub-Saharan 
Africa. Even though ART reduces plasma viral load to low 
levels, there is a concern that spikes of HIV genital shedding 
may occur during episodes of STIs, possibly increasing the 
risk of HIV transmission [110-112]. Further data are needed 
from studies of genital shedding of HIV in index cases with 
different CD4 counts, plasma viral load and ART treatment 
status, and with or without concomitant STIs. Future 
observational analyses of HIV transmission to sexual 
partners should also collect prospective data on the incidence 
of STIs. 
Effects of UTT on HIV Transmission at Population Level 
 The rationale underpinning the UTT strategy is that a 
large proportion of HIV transmission events take place in 
index cases who are not on ART because they have not yet 
been diagnosed HIV-positive, have been diagnosed but are 
not yet eligible for ART, or are eligible for ART but have 
not yet started on ART. The impact of UTT on HIV 
transmission will depend partly on the size of this untreated 
proportion and on the extent to which UTT can reduce it. 
However, the overall impact on HIV incidence at population-
level will also reflect indirect effects of the intervention, 
since the new cases of HIV infection averted will lead to a 
further reduction in index cases and hence future 
transmission events. Prediction of population-level impact 
under different conditions is complex and is likely to depend 
on mathematical modelling which needs to be based on 
realistic assumptions and input parameters. However, proof 
of concept is likely to come from a cluster-randomised trial 
of the UTT strategy and this is discussed below. 
 Initial work is needed to address the question of what 
proportions of new HIV infections in different populations 
are attributable to index cases at different CD4 counts and 
stages of HIV progression. This is likely to involve a 
combination of data collection and mathematical modelling. 
Data are needed on uptake of HIV testing, delay before new 
HIV infections are diagnosed, coverage of ART, delay 
before onset of ART and the CD4 count at which ART 
commences. All these parameters are likely to vary 
substantially between countries and settings. Together with 
the available data from observational studies on the 
association between stage of HIV progression and HIV 
transmissibility, these data can be used in mathematical 
models to estimate the proportion of HIV transmission 
events occurring at different CD4 counts or stages of HIV 
progression. 
 Based on this initial work, the mathematical models can 
then be used to explore the likely effects on HIV 
transmission of a UTT intervention. Scenario analysis will 
be needed to examine the effect of a range of assumptions 
about the performance of UTT, including uptake of testing, 
acceptance of immediate treatment and adherence to ART 
[113]. Relatively simple models can be used to make rough 
estimates of short-term effects on transmission based only on 
changes in the treatment status of index cases and 
consequent changes in HIV transmissibility. Long-term 
projections of population-level impact, however, will require 
the application of more sophisticated HIV transmission 
models that take account of sexual networks and the 
dynamics of transmission in the population as well as 
capturing the effects of behavioural disinhibition and indirect 
“herd” effects resulting from reductions in the number of 
new index cases. 
 The feasibility studies discussed in earlier sections of this 
paper would help to provide the data to guide parameter 
choice for future evidence-based modelling work. Where 
data are unavailable, a range of plausible assumptions can be 
explored. Modelling can also be done to investigate the 
effects of different aspects of UTT implementation, such as 
the proposed frequency of HIV testing and re-testing in the 
community as well as levels of coverage and uptake. 
 Implementation of UTT will depend not only on 
evidence of population-level effectiveness but also on 
affordability and cost-effectiveness. Proposed feasibility 
studies of UTT interventions should collect detailed data on 
costs of implementation and the components of these costs. 
These data can be used by economists to estimate the likely 
costs of UTT interventions in a range of settings with 
different input prices. Data on estimated costs can be 
integrated with the mathematical models to obtain estimates 
of cost-effectiveness under different conditions, which may 
be expressed for example as cost per HIV infection averted 
or cost per disability-adjusted life year (DALY). These 
estimates will be based on differences in projected numbers 
of HIV infections over a defined study period (for example 
10 or 15 years) for the proposed UTT intervention and the 
current level of diagnosis and treatment, combined with data 
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on differences in costs under the two scenarios. When 
computing costs, it is important that account is taken not 
only of the direct costs of implementing the UTT 
intervention but also of costs averted due to future 
reductions in HIV infections needing care and other services 
as well as reductions in HIV-related morbidity due to earlier 
treatment and higher uptake of treatment. Previous 
modelling work suggests that the saving of hospital and 
other health-care costs for these illnesses will largely offset 
the costs of implementing UTT at least in a South African 
setting [12,21,114]. It may also be helpful to model the cost-
effectiveness of UTT compared with that of a more limited 
intervention aimed at expanding testing and increasing the 
numbers of patients treated promptly according to current 
treatment guidelines. 
 While modelling should provide useful projections of 
cost-effectiveness under a range of conditions, there will 
always be uncertainties about the validity of such projections 
given the large number of assumptions required, many not 
well supported by empirical evidence. UTT represents a 
controversial and logistically very challenging intervention, 
with a range of possible adverse effects, ranging from 
increased stigma and behavioural disinhibition to increases 
in drug resistance and over-burdening of health services. A 
decision to go ahead with wide-scale implementation is 
likely to depend on proof of concept obtained through one or 
more rigorously conducted cluster-randomised trials. Such 
trials could directly collect data on population-level impact 
on HIV incidence as well as on implementation costs and 
many other outcomes including the potential adverse effects 
noted above. 
CLUSTER-RANDOMISED TRIALS OF UTT: DESIGN 
CONSIDERATIONS 
Introduction 
 We have argued that rigorous proof of concept of UTT as 
an HIV prevention strategy is likely to depend on evidence 
from a cluster-randomised trial (CRT) of the impact of UTT 
at population level. In this section, we briefly discuss key 
design aspects of such a trial, which is likely to involve 
random allocation of a number of study communities to the 
UTT intervention or a standard of care control arm, and 
follow-up over several years to record effects on HIV 
incidence at population level. 
Rationale for CRT Design 
 RCTs remain the gold standard for the evaluation of 
health interventions, where they are feasible. Cluster 
randomisation is called for where the intervention has by its 
nature to be implemented at population level, as is the case 
for UTT. Moreover, cluster randomisation allows the total 
effect of the intervention, including indirect “herd” effects, 
to be captured [115,116]. By comparison of both effects and 
costs between intervention and control clusters, a CRT can 
provide rigorous empirical estimates of effectiveness and 
cost-effectiveness to guide the decisions of policy-makers 
regarding the implementation of health interventions. 
 
Study Populations and Definition of Clusters 
 It is likely that any CRT of the UTT strategy will be a 
multi-site trial involving sites in several countries in sub-
Saharan Africa, for two reasons. First, a multi-country study 
will help to ensure that the results of the trial are 
generalisable and reflect the performance of the strategy 
under a range of conditions. Second, the size of such a trial 
and the large number of clusters required are likely to call for 
a multi-country study. 
 It is likely that the effects of the intervention will show 
some variation due to differences in the existing coverage of 
testing and treatment services, variations in the uptake and 
delivery of the UTT strategy, underlying differences in the 
epidemiology and transmission dynamics of HIV and other 
contextual factors. It is important to note that the proposed 
CRT will be powered to determine the overall effect of UTT, 
averaged over sites. While the data may give some indication 
of relative effects of UTT in different settings, the study will 
not be powered to provide precise data on variations in 
effectiveness between countries. Once again, there will be a 
role for mathematical modelling in taking the empirical data 
from the CRT and using them to provide refined estimates of 
effectiveness and cost-effectiveness in different settings. 
 The choice of clusters is likely to depend on the level at 
which the intervention is implemented, as well as the 
transmission dynamics of HIV infection. Ideally, to correctly 
capture the indirect effects of the intervention and to avoid 
contamination due to sexual contacts with individuals from 
outside the cluster, the cluster would be large enough to 
ensure that most sexual contacts occur within the cluster. 
However, the requirement for a relatively large number of 
clusters and the need to constrain costs will necessitate a 
compromise between feasibility and validity. In practice, the 
cluster might be defined as the catchment population of a 
health facility through which the UTT intervention is to be 
delivered and coordinated. To minimise contamination, and 
problems due to overlapping catchments of different health 
facilities, it may be preferable to select widely dispersed 
rural communities or small towns, rather than areas within 
large urban conurbations. 
Standard of Care in Control Arm 
 A critical component of the CRT design is comparison of 
effects in intervention clusters with comparable clusters in a 
control arm. An important issue for CRTs of UTT is what 
services will be provided in the control arm. To maximise 
study power and to provide the most relevant evidence for 
health policy, it would arguably be desirable for the control 
arm to receive the current level of service provision in the 
study community with no additional interventions. However, 
the ethical acceptability of enrolling and following up study 
communities where currently recommended criteria for 
service provision are not adhered to, as is likely to be the 
case in many resource-poor settings, would need to be 
carefully considered. International guidelines on this issue 
have been an area of intense debate and disagreement, and 
are under constant review. Responsibilities to trial  
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participants have to be balanced against the urgent need for 
valid data to guide national and international policy, as well 
as concerns over providing enhanced service levels which 
are unlikely to be sustained after the end of a study. 
 One option would be to enhance service provision to an 
acceptable “standard of care”, ensuring that anyone wishing 
to be tested for HIV has easy and convenient access to a 
VCT service of acceptable quality, and that all those 
diagnosed HIV-positive have access to ART according to 
current national treatment guidelines. This would certainly 
result in higher ART coverage than at present, thus diluting 
any difference in outcomes between the study arms, and this 
would need to be allowed for in sample size calculations. An 
alternative is to provide communities in the control arm with 
some other intervention, unrelated to HIV infection, that 
would be of intrinsic value to the community. 
 It is likely that random samples of adults from the study 
communities will be followed up to measure effects on HIV 
incidence. Enrolling individuals to a research cohort of this 
kind may impose additional constraints regarding the 
responsibilities of the research team. What access would this 
cohort have to HIV counselling, testing and treatment? 
Would there be an expectation that proven HIV prevention 
methods (such as male circumcision) should be made 
available to these cohorts? These are difficult questions that 
would require careful consideration and discussion with 
national authorities and ethical review committees. 
Duration of Follow-Up 
 It is likely that the UTT strategy will take several years to 
show its full effect for two main reasons. First, it will take 
some time to introduce the intervention into the study 
communities and to expand coverage so that a maximal 
proportion of the population have been tested and a high 
proportion of those diagnosed HIV-positive have been 
started on ART. Second, indirect “herd” effects of the 
intervention will accumulate over time, and a long enough 
follow-up period is needed for these to be captured. 
Similarly, it may also take some time for potential adverse 
effects of the intervention, such as HIV-related stigma or 
behavioural disinhibition, to be observable. Conversely, 
some initial problems with the intervention may be resolved 
over time; for example, it may take time to establish the trust 
of the community in the confidentiality and quality of the 
services, and uptake may increase substantially once this has 
been achieved. 
 Previous mathematical modelling showed that UTT 
would have an immediate effect on HIV incidence but that 
effects would accumulate over time. “Elimination” of HIV 
as a public health problem was only projected after 15-20 
years. For these reasons, a CRT would require a long enough 
follow-up period so that at least the early effects of the 
intervention are detectable, and this is likely to be at least 
two to three years. 
Primary and Secondary Endpoints 
 The primary objective of a CRT would be to measure the 
impact of the UTT intervention on HIV incidence at 
population level, and so HIV infection in the general 
population of the study communities would be the primary 
endpoint. If a reliable assay that can detect recent HIV 
infection is available and validated, then HIV incidence 
could be measured through a cross-sectional survey of a 
random sample of the population at the end of the follow-up 
period. Unfortunately, none of the existing assays have been 
validated in the likely study populations for a CRT, where 
HIV subtypes differ from those that predominate in settings 
where most of these assays have been developed. If such 
assays are not available, measurement of HIV incidence is 
likely to require enrolment and follow-up of a cohort which 
might be a random sample of the adult population. Cohort 
follow-up brings a number of problems, including 
difficulties in ensuring a high rate of follow-up, particularly 
when mobility and migration rates are high, and “cohort 
attrition” leading to declining incidence over time. 
 There are likely to be numerous secondary endpoints and 
these are likely to include HIV-related morbidity and 
mortality; uptake of testing; uptake of treatment; adherence 
and treatment failure; drug resistance and toxicity; HIV-
related stigma; TB incidence; HIV vertical transmission; and 
behavioural disinhibition. 
Sample Size 
 Special methods are required for sample size 
determination for a CRT [116]. These depend on the 
expected incidence of HIV; the effect size on which the 
study is to be powered; and the between-cluster coefficient 
of variation in the primary endpoint. Both the number of 
clusters per study arm and the number of individuals to be 
followed up in each cluster need to be specified. Note that 
the latter may be a random sample of the community, and it 
is not necessary to follow up the entire population of each 
community. 
 To illustrate the likely size of a CRT, suppose HIV 
incidence in adults is approximately 1 per 100 person-years 
in control communities, and we wish to detect a 40% 
reduction in HIV incidence with 90% power, and the 
coefficient of variation is 0.25 indicating that HIV incidence 
varies roughly between 0.5 and 1.5 per 100 person-years in 
the control arm. Then if we select a random sample of 1000 
adults in each cluster and follow them up for 3 years giving 
2550 person-years of observation per cluster (assuming 15% 
loss of person-years), we would need 11 clusters per arm (a 
total of 22 clusters) with an unmatched design. Table 4 
shows sample size requirements for a CRT under a range of 
assumptions. 
CONCLUSIONS 
 In this paper, we have reviewed the research questions 
that need to be addressed to provide the evidence needed to 
inform policy on the implementation of the UTT strategy, 
and outlined possible research methods that could be used to 
answer these. Some of these studies can be done using 
existing data, but new field research will also be needed. 
 In particular, we propose a phased sequence of studies, 
commencing with pilot studies looking at the feasibility and 
acceptability of the intervention. If these show favourable 
results, it might then be appropriate to proceed to a full-scale 
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CRT to measure the impact of the intervention on HIV 
incidence at population level, as well as a wide range of 
secondary outcomes. Such a trial would produce rigorous 
evidence on the beneficial and adverse effects of the UTT 
intervention which, together with cost data, would provide 
estimates of cost-effectiveness to guide policy decisions on 
the potential wide-scale implementation of the intervention. 
 One of the key limitations of the proposed CRT is that it 
is unlikely to be feasible to follow up the study communities 
for more than a few years, whereas model projections show 
that the full impact of such an approach may not be seen for 
15 to 20 years. However, these projections do predict a 
substantial early effect of the intervention, and observations 
confirming such an effect would provide strong support for 
wider introduction. Mathematical models could be fitted to 
data from a CRT on early effects of UTT and used to refine 
estimates of longer-term impact. In any case, the need for 
more effective prevention strategies is urgent, and cannot 
wait for the results of a trial extending for 10 years or more. 
 It is by no means certain that initial feasibility studies 
will show the UTT approach to be feasible or acceptable in 
resource-poor settings. More limited and targeted approaches 
to intensified delivery of HIV testing and treatment, while 
not resulting in “elimination”, may nevertheless have an 
appreciable effect on HIV transmission. We suggest that 
work should continue on such approaches in parallel to the 
proposed initial studies of UTT. 
 The concept of UTT fits into the broader paradigm of 
combination HIV prevention. There is increasing recognition 
that single interventions are unlikely to be sufficient to bring 
the HIV epidemic under effective control in the most 
severely affected countries, and that a combination of 
partially effective methods will be required [117]. UTT itself 
represents a combination prevention tool as it involves a 
combination of testing, linkage to care and early treatment. 
Achieving high uptake of testing through a UTT programme 
provides an opportunity to offer other proven interventions 
such as male circumcision, condoms and potentially 
microbicides or oral PrEP. The CRT design discussed above 
could be extended to measure the population-level impact of 
a combination prevention package that includes UTT 
combined with other interventions. 
 Whether or not the research studies outlined in this paper 
show that UTT is a feasible and effective HIV prevention 
intervention, they will provide a wide range of data that will 
be of value in guiding the strengthening of services for 
testing and treatment in sub-Saharan Africa - for both 
individual and public health benefit. 
ACKNOWLEDGEMENTS 
 We are grateful to Debby Watson-Jones for her helpful 
comments on a draft version of this paper. We have also 
benefitted from discussion of research questions and 
methods related to UTT with Liz Corbett, Helen Ayles, 
Christophe Fraser, Sheena McCormack, Abdul Babiker, 
Anatoli Kamali, Paula Mundeiri, David Ross and other 
members of the PopART team. We thank the reviewer from 
Current HIV Research for the helpful comments before 
finalisation of this paper. 
 
Table 4. Sample Size Requirements for Cluster Randomised Trial of Universal Testing and Treatment (UTT) for HIV Prevention. 
Table Shows Number of Clusters Required in Each Study Arm Under a Range of Scenarios 
 
HIV Incidence in 
Control Arm 
(/100py) 
Sample Size of 
Cohort Per Cluster * 
Coefficient of 
Variation 
Impact on HIV 
Incidence (1 - RR) x 
100% 
Power 
Clusters Required 
Per Study Arm 
1.0 ** 1000 0.25 40% 90% 11 
0.5 
1.0 
1.5 
2.0 
1000 
1000 
1000 
1000 
0.25 
0.25 
0.25 
0.25 
40% 
40% 
40% 
40% 
90% 
90% 
90% 
90% 
15 
11 
10 
9 
1.0 
1.0 
1.0 
500 
1000 
2000 
0.25 
0.25 
0.25 
40% 
40% 
40% 
90% 
90% 
90% 
15 
11 
9 
1.0 
1.0 
1.0 
1000 
1000 
1000 
0.20 
0.25 
0.30 
40% 
40% 
40% 
90% 
90% 
90% 
9 
11 
14 
1.0 
1.0 
1.0 
1000 
1000 
1000 
0.25 
0.25 
0.25 
30% 
40% 
50% 
90% 
90% 
90% 
20 
11 
7 
1.0 
1.0 
1000 
1000 
0.25 
0.25 
40% 
40% 
80% 
90% 
9 
11 
*Assumes cohort is followed up for 3 years with 15% loss of person-years of follow-up. ** Top row shows default scenario discussed in text. Suppose HIV incidence in adults is 
approximately 1 per 100 person-years in control communities, we wish to detect a 40% reduction in HIV incidence with 90% power and the coefficient of variation is 0.25 indicating 
that HIV incidence varies roughly between 0.5 and 1.5 per 100 person-years in the control arm. Then if we select a random sample of 1000 adults in each cluster and follow them up 
for 3 years giving 2550 person-years of observation per cluster (assuming 15% loss of person-years), we would need 11 clusters per arm (a total of 22 clusters) with an unmatched 
design. 
UTT, Universal Testing and Treatment; py, person-years; RR, relative risk. 
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START = Strategic Timing of Antiretroviral Treatment 
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